Guillain-barre syndrome associated with peginterferon alfa-2a for chronic hepatitis C: A case report

World Journal of Hepatology

Volumn 2, Issue 4, 2010, Pages 162-166

  Niazi, Mumtaz A ^a   Azhar, Ashaur ^a   Tufail, Kashif ^a   Feyssa, Eyob L ^a   Penny, Stephen F ^b   McGregory, Marlene ^a   Araya, Victor ^a   Ortiz, Jorge A ^a  

^a EINSTEIN MEDICAL CENTER   (United States)

^b Bay Health Corporation   (United States)

Author keywords

Acute demyelinating polyneuropathy; Chronic hepatitis C; Guillain barre syndrome; Pegylated interferon; Polyneuropathy

Indexed keywords

EID: 84875375768     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v2.i4.162     Document Type: Article

References (16)

1. World Health Organization. Hepatitis C. Last updated: 2008-01-25. Available from: URL: http://www.who.int/immunization/topics/hepatitis_c/en/index.html
2. Kim WR. The burden of hepatitis C in the United States. Hepatology 2002; 36: S30-S34
3. Deuffic-Burban S, Poynard T, Sulkowski MS, Wong JB. Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States. J Viral Hepat 2007; 14: 107-115
4. Ghany MG, Strader DB, Thomas DL, Seeff LB. American Association for the Study of Liver Diseases. Diagnosis, Management, and Treatment of Hepatitis C: An Update. Hepatology 2009; 49: 1335-1374
5. PEGASYS® Pegylated interferon (peginterferon) alfa-2a: Drug information. Hoffmann-La Roche Inc; 2009
6. Lee MY, Cho H, Kim YM, Lee JS. [A case of Bell's palsy associated with peginterferon Alfa-2a and ribavirin therapy for chronic hepatitis C virus infection]. Korean J Hepatol 2006; 12: 444-448
7. Khiani V, Kelly T, Shibli A, Jensen D, Mohanty SR. Acute inflammatory demyelinating polyneuropathy associated with pegylated interferon alpha 2a therapy for chronic hepatitis C virus infection. World J Gastroenterol 2008; 14: 318-321
8. Hirotani M, Nakano H, Ura S, Yoshida K, Niino M, Yabe I, Sasaki H. Chronic inflammatory demyelinating polyneuropathy after treatment with interferon-alpha. Intern Med 2009; 48: 373-375
9. Meriggioli MN, Rowin J. Chronic inflammatory demyelinating polyneuropathy after treatment with interferonalpha. Muscle Nerve 2000; 23: 433-435
10. Criteria for diagnosis of Guillain-Barré syndrome. Ann Neurol 1978; 3: 565-566
11. Ogawara K, Kuwabara S, Mori M, Hattori T, Koga M, Yuki N. Axonal Guillain-Barré syndrome: relation to antiganglioside antibodies and Campylobacter jejuni infection in Japan. Ann Neurol 2000; 48: 624-631
12. Ropper AH. The Guillain-Barré syndrome. N Engl J Med 1992; 326: 1130-1136
13. Spudich SS, Nilsson AC, Lollo ND, Liegler TJ, Petropoulos CJ, Deeks SG, Paxinos EE, Price RW. Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment. BMC Infect Dis 2005; 5: 98
14. Haber P, DeStefano F, Angulo FJ, Iskander J, Shadomy SV, Weintraub E, Chen RT. Guillain-Barré syndrome following influenza vaccination. JAMA 2004; 292: 2478-2481
15. Gordon PH, Wilbourn AJ. Early electrodiagnostic findings in Guillain-Barré syndrome. Arch Neurol 2001; 58: 913-917
16. Hughes RA, Wijdicks EF, Barohn R, Benson E, Cornblath DR, Hahn AF, Meythaler JM, Miller RG, Sladky JT, Stevens JC. Practice parameter: immunotherapy for Guillain-Barré syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2003; 61: 736-740